Lebenthal Asset Management’s Core Laboratories CLB Stock Holding History

Lebenthal Asset Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$2.38M	Sell	20,620 -172	-0.8%	-$20K	0.3%	107
2016 Q4	$2.5M	Sell	20,792 -911	-4%	-$101K	0.32%	98
2016 Q3	$2.44M	Sell	21,703 -420	-2%	-$48.4K	0.32%	102
2016 Q2	$2.74M	Buy	+22,123	New	+$2.67M	0.36%	81

Other funds holding CLB

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Lebenthal Asset Management's CLB Position: Q1 2017 in Review

Lebenthal Asset Management reduced its Core Laboratories (CLB) stake by 0.83% in Q1 2017, selling an estimated $20K and leaving 20,620 shares worth $2.38M. The position accounts for 0.3% of the portfolio, ranked #107.

Lebenthal Asset Management first reported a position in CLB in Q2 2016 and has held it in 4 quarters since. The position peaked at $2.74M in Q2 2016. 360 funds tracked by Wall St. Rank hold CLB as of Q1 2017.

Lebenthal Asset Management held 20,620 shares of Core Laboratories worth $2.38M as of Q1 2017.
Lebenthal Asset Management sold 172 Core Laboratories shares in Q1 2017, an estimated $20K.
Core Laboratories made up 0.3% of Lebenthal Asset Management's portfolio in Q1 2017, its #107 holding.
Lebenthal Asset Management first reported a position in Core Laboratories in Q2 2016 and has held it in 4 quarters since.
Lebenthal Asset Management's Core Laboratories position peaked at $2.74M in Q2 2016.
360 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2017.

Based on Lebenthal Asset Management's 13F filing for Q1 2017, filed 15 May 2017.